Complex Regional Pain Syndrome (CRPS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Complex Regional Pain Syndrome (CRPS) Market Outlook
Thelansis’s “Complex Regional Pain
Syndrome (CRPS) Market Outlook, Epidemiology, Competitive Landscape, and Market
Forecast Report – 2024 To 2034" covers disease overview, epidemiology,
drug utilization, prescription share analysis, competitive landscape, clinical
practice, regulatory landscape, patient share, market uptake, market forecast,
and key market insights under the potential Complex Regional Pain Syndrome
(CRPS) treatment modalities options for eight major markets (USA, Germany,
France, Italy, Spain, UK, Japan, and China).
Complex
Regional Pain Syndrome (CRPS) Overview
Complex
regional pain syndrome (CRPS), or Sudeck’s dystrophy or reflex sympathetic
dystrophy, is a painful condition characterized by various symptoms, including
pain, sensory disturbances, Sudo- and vasomotor abnormalities, trophic changes,
and impaired motor function. CRPS can develop due to different levels or types
of tissue damage. In some cases, it has even been observed without any injury,
often arising from extended periods of immobilization. Among the most common
causes of CRPS is a fracture, while surgery is another frequent trigger. Other
injuries or insults that can incite CRPS encompass sprains, contusions, crush
injuries, and surgical procedures. CRPS is categorized into two main types:
type I, formerly known as reflex sympathetic dystrophy, and type II, previously
termed causalgia. Type I occurs without associated nerve trauma, whereas type
II arises following known nerve injuries. Additionally, CRPS is further
subdivided into “warm” versus “cold” varieties, and sympathetically-maintained
(SMP) versus sympathetically-independent (SIP) forms, which can influence both
the prognosis and available treatment options. Patients with CRPS receive
treatment from a diverse range of medical specialists, including
anaesthesiologists, (orthopaedic) surgeons, neurologists, rheumatologists, and
rehabilitation centers, due to the multifaceted nature of the condition and its
wide array of symptoms. It’s important to note that there are currently no
medications approved by the Food and Drug Administration (FDA) specifically for
treating CRPS. Consequently, treatment protocols frequently require the use of
off-label medications. Limitations in available medications could potentially
restrict options for both healthcare providers and patients in managing their
symptoms. The prognosis of CRPS varies, with instances of spontaneous remission
and refractory clinical presentations observed. However, early intervention may
lead to improved outcomes. Long-standing CRPS can be associated with
complications such as dystonia, cognitive executive dysfunction, adrenal
insufficiency, gastroparesis, and irritable bowel syndrome.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment